DelveInsight’s “Prader-Willi Syndrome Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Prader-Willi Syndrome, historical and forecasted epidemiology as well as the Prader-Willi Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The Prader-Willi Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Prader-Willi Syndrome pipeline products will significantly revolutionize the Prader-Willi Syndrome market dynamics.
To Know in detail about the Prader-Willi Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Prader-Willi Syndrome Market Forecast
Some of the key facts of the Prader-Willi Syndrome Market Report:
- The Prader-Willi Syndrome market size was valued ~USD 600 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).
- In February 2026, Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that Institutional Review Board (IRB) approval has been granted in the United States for an amended protocol to its ongoing Phase 3 HERO pivotal clinical trial evaluating ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi Syndrome (PWS). The amended protocol, submitted to the U.S. Food and Drug Administration (FDA), lowers the minimum age of eligibility for trial participation from 10 to 7 years old.
- In September 2025, Acadia Pharmaceuticals Inc. has decided to discontinue development of ACP-101, an intranasal carbetocin, for treating hyperphagia in Prader-Willi syndrome after its Phase III trial setback. The 12-week, double-blind, randomized study failed to meet the primary endpoint, as the therapy did not show a statistically significant benefit compared to placebo.
- In April 2025, Vykat XR featured an extended-release formulation of diazoxide choline, the crystalline salt form of diazoxide. While its precise mechanism of action remains uncertain, it is believed to reduce hyperphagia in individuals with Prader-Willi syndrome by activating ATP-sensitive potassium channels in the hypothalamus. The FDA approval was based on results from a 16-week, Phase 3, double-blind, placebo-controlled, randomized withdrawal trial (ClinicalTrials.gov Identifier: NCT03714373), which was preceded by an open-label treatment phase with diazoxide choline extended-release.
- In March 2025, The FDA approved Soleno Therapeutics’ diazoxide choline (DCCR) extended-release tablets, branded as Vykat XR, for managing hyperphagia in individuals aged 4 and older with Prader-Willi syndrome (PWS). This marks a significant milestone as Vykat XR becomes the first approved therapy specifically targeting hyperphagia in PWS. DCCR is a proprietary, once-daily extended-release formulation of diazoxide choline, the crystalline salt form of diazoxide, designed to address the excessive hunger characteristic of the condition.
- In March 2025, Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company focused on developing innovative treatments for rare diseases, has announced that the U.S. Food and Drug Administration (FDA) has approved VYKAT XR (diazoxide choline) extended-release tablets, formerly known as DCCR, for treating hyperphagia in adults and children aged 4 and older with Prader-Willi syndrome (PWS).
- In March 2025, The FDA has granted approval to Soleno Therapeutics’ diazoxide choline (DCCR) extended-release tablets, branded as Vykat XR, for the treatment of Prader-Willi syndrome (PWS) in patients aged 4 years and older with hyperphagia. DCCR, a unique extended-release formulation containing diazoxide choline (the crystalline salt of diazoxide), is administered once daily and becomes the first treatment specifically targeting hyperphagia in PWS.
- The overall market size for PWS in the US was projected to be approximately USD 500 million in 2023, with expectations for growth throughout the forecast period (2024-2034).
- In EU4 and the UK, Germany held the largest market share, with a market size of approximately USD 30 million in 2023, and this is anticipated to increase during the forecast period (2024-2034).
- There is significant uncertainty regarding the therapies from Gedeon Richter and Palobiofarma due to a lack of substantial evidence on their safety and efficacy. In contrast, Palobiofarma’s PBF-999 is anticipated to be launched first in Spain.
- In 2023, the US had the highest number of prevalent cases of PWS among the 7MM, totaling approximately 22,600 cases, which are projected to rise during the forecast period.
- In 2023, Germany had the highest number of total prevalent cases of PWS among the EU4 and the UK, whereas Spain recorded the lowest number of cases.
- Estimates indicate that in Japan, PWS was most commonly seen in the 18-40 age group, representing over 38% of all cases in 2023.
- In 2023, within the United States, the paternal microdeletion subtype represented the largest share of genetic subtype-specific cases of PWS, comprising around 70% of cases, while the translocation subtype was the least prevalent.
- Key Prader-Willi Syndrome Companies: Novo Nordisk, Pfizer, Sandoz, Harmony Biosciences, Soleno Therapeutics, Harmony Biosciences, ACADIA Pharmaceuticals, Aardvark Therapeutics, Gedeon Richter, Palobiofarma, ConSynance Therapeutics, and others
- Key Prader-Willi Syndrome Therapies: NORDITROPIN, GENOTROPIN, OMNITROPE, WAKIX (pitolisant), Diazoxide Choline Controlled-Release (DCCR), WAKIX (pitolisant), DCCR (diazoxide choline), Carbetocin (LV-101), ARD-101, RGH-706, PBF-999, CSTI-500, and others
- The Prader-Willi Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Prader-Willi Syndrome pipeline products will significantly revolutionize the Prader-Willi Syndrome market dynamics.
Prader-Willi Syndrome Overview
Prader-Willi Syndrome (PWS) is a complex genetic disorder that affects many parts of the body. The condition is characterized by weak muscle tone (hypotonia) and feeding difficulties in infancy, followed by excessive eating and gradual development of obesity. Individuals with Prader-Willi Syndrome typically have intellectual disability, behavioral problems, and distinctive physical features such as almond-shaped eyes, a narrowing of the head at the temples, and a turned-down mouth.
Get a Free sample for the Prader-Willi Syndrome Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/prader-willi-syndrome-market
Prader-Willi Syndrome Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Prader-Willi Syndrome Epidemiology Segmentation:
The Prader-Willi Syndrome market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
- Total Prevalence of Prader-Willi Syndrome
- Prevalent Cases of Prader-Willi Syndrome by severity
- Gender-specific Prevalence of Prader-Willi Syndrome
- Diagnosed Cases of Episodic and Chronic Prader-Willi Syndrome
Download the report to understand which factors are driving Prader-Willi Syndrome epidemiology trends @ Prader-Willi Syndrome Epidemiology Forecast
Prader-Willi Syndrome Drugs Uptake and Pipeline Development Activities
WAKIX (pitolisant) – Harmony Biosciences
Pitolisant is a selective histamine H3 receptor antagonist/inverse agonist that enhances histamine release, a neurotransmitter associated with wakefulness. While its exact mechanism in Prader-Willi Syndrome (PWS) remains unclear, it is believed to improve symptoms through this pathway. Originally developed by Bioprojet, Harmony Biosciences holds exclusive US rights for its development and commercialization. WAKIX is already approved by the US FDA for treating excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy. Although not yet approved for PWS, it is under clinical evaluation and received Orphan Drug designation for this indication in February 2024. In April 2024, Harmony initiated the Phase III TEMPO trial to assess pitolisant’s safety and efficacy in managing EDS and behavioral symptoms in PWS patients aged 6 years and above. The company is also advancing another candidate, HBS-102, for PWS.
Diazoxide Choline Controlled-Release (DCCR) – Soleno Therapeutics
DCCR is an extended-release, once-daily formulation of diazoxide choline, derived from diazoxide, a drug with long-standing use in rare conditions but not yet approved for PWS. Soleno Therapeutics has secured strong patent protection for its use in PWS. In April 2024, the US FDA granted Breakthrough Therapy designation to diazoxide choline for treating hyperphagia in PWS patients aged 4 years and older. Subsequently, in June 2024, Soleno submitted a New Drug Application (NDA) to the FDA seeking approval of DCCR tablets for managing hyperphagia in this patient population.
Prader-Willi Syndrome Therapies and Key Companies
- NORDITROPIN: Novo Nordisk
- GENOTROPIN: Pfizer
- OMNITROPE: Sandoz
- WAKIX (pitolisant): Harmony Biosciences
- Diazoxide Choline Controlled-Release (DCCR): Soleno Therapeutics
- WAKIX (pitolisant): Harmony Biosciences
- DCCR (diazoxide choline): Soleno Therapeutics
- Carbetocin (LV-101): ACADIA Pharmaceuticals
- ARD-101: Aardvark Therapeutics
- RGH-706: Gedeon Richter
- PBF-999: Palobiofarma
- CSTI-500: ConSynance Therapeutics
Download free sample report now: Prader-Willi Syndrome Treatment Market and Competitive Analysis
Scope of the Prader-Willi Syndrome Market Report
- Study Period: 2020-2034
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Prader-Willi Syndrome Companies: Novo Nordisk, Pfizer, Sandoz, Harmony Biosciences, Soleno Therapeutics, Harmony Biosciences, ACADIA Pharmaceuticals, Aardvark Therapeutics, Gedeon Richter, Palobiofarma, ConSynance Therapeutics, and others
- Key Prader-Willi Syndrome Therapies: NORDITROPIN, GENOTROPIN, OMNITROPE, WAKIX (pitolisant), Diazoxide Choline Controlled-Release (DCCR), WAKIX (pitolisant), DCCR (diazoxide choline), Carbetocin (LV-101), ARD-101, RGH-706, PBF-999, CSTI-500, and others
- Prader-Willi Syndrome Therapeutic Assessment: Prader-Willi Syndrome current marketed and Prader-Willi Syndrome emerging therapies
- Prader-Willi Syndrome Market Dynamics: Prader-Willi Syndrome market drivers and Prader-Willi Syndrome market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Prader-Willi Syndrome Unmet Needs, KOL’s views, Analyst’s views, Prader-Willi Syndrome Market Access and Reimbursement
Discover more about therapies set to grab major Prader-Willi Syndrome market share @ Prader-Willi Syndrome Treatment Landscape
Table of Content
- Key Insights – Prader-Willi Syndrome
- Report Introduction – Prader-Willi Syndrome
- Executive Summary – Prader-Willi Syndrome
- Prader-Willi Syndrome Market Overview at a Glance
- Key Events – Prader-Willi Syndrome
- Prader-Willi Syndrome Epidemiology and Market Forecast Methodology
- Prader-Willi Syndrome Disease Background and Overview
- Prader-Willi Syndrome Treatment and Management
- Prader-Willi Syndrome Epidemiology and Patient Population
- Prader-Willi Syndrome Patient Journey
- Prader-Willi Syndrome Marketed Drugs
- Prader-Willi Syndrome Emerging Drugs
- Prader-Willi Syndrome Market Analysis
- Prader-Willi Syndrome Unmet Needs
- Prader-Willi Syndrome SWOT Analysis
- Prader-Willi Syndrome KOL Views
- Prader-Willi Syndrome Market Access and Reimbursement
- Prader-Willi Syndrome Appendix
- DelveInsight Capabilities – Prader-Willi Syndrome
- Disclaimer – Prader-Willi Syndrome
- About DelveInsight – Prader-Willi Syndrome
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting